Q3 Earnings Forecast for ESPR Issued By HC Wainwright

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at HC Wainwright issued their Q3 2025 earnings estimates for Esperion Therapeutics in a research report issued on Tuesday, March 4th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will earn ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.06 EPS and FY2028 earnings at $0.20 EPS.

Several other equities research analysts have also recently issued reports on ESPR. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price on the stock. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, JMP Securities restated a “market outperform” rating and issued a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Trading Up 6.3 %

Shares of ESPR stock opened at $1.69 on Friday. Esperion Therapeutics has a 12-month low of $1.56 and a 12-month high of $3.94. The firm’s 50 day moving average is $1.96 and its 200 day moving average is $2.08. The stock has a market capitalization of $332.99 million, a P/E ratio of -2.64 and a beta of 1.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Cibc World Markets Corp purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth $39,000. SJS Investment Consulting Inc. bought a new stake in shares of Esperion Therapeutics during the 4th quarter valued at $55,000. Versor Investments LP bought a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at $44,000. Crestline Management LP bought a new stake in shares of Esperion Therapeutics during the 4th quarter valued at $63,000. Finally, SLT Holdings LLC bought a new stake in shares of Esperion Therapeutics during the 4th quarter valued at $66,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.